Jiali Medical Technology (Guangzhou) Co., Ltd. will enter Guangzhou International Bio Island in 2020. Its headquarters, Arbele Limited, is located in Hong Kong Science Park, and its R&D institutions are located in the United States and Hong Kong. Abel is a pharmaceutical technology company focusing on gastrointestinal cancer immunotherapy drugs and technological innovation. It is committed to improving human health and creating value for society through breakthrough innovations in medical technology.

Founder Dr. Manqing Lu discovered Cadherin-17 (CDH17) and obtained a global patent for its use as a disease marker and therapeutic target. CDH17 is highly expressed in gastrointestinal cancer genomes and tumor tissues, and has been shown to be a bona fide oncogene in gastrointestinal cancers. Knockdown and immunotargeting of CDH17 inhibited tumor growth, indicating its great therapeutic potential.

Abelox has developed a series of diagnostic and therapeutic products that utilize the properties of CDH17 to treat gastrointestinal cancer. Abelox's core product pipeline includes novel cancer diagnostic technologies, patented bispecific antibody biologics, and CAR-T therapy technologies. The goal is to submit a Biologics License Application (BLA) to the U.S. FDA and China's NMPA through Fast Track in 2022 .

As a member of the "Biomedical Technology Incubation Program" and "Enterprise Leaping Program" of the Hong Kong Science and Technology Park, Abel has received strong financial support from the government to help push the bispecific antibody ARB202 into the IND stage.

Awarded the 2020 Asia-Pacific Top Biotechnology Start-up Company, Hong Kong's Most Outstanding Service Award (Biotechnology) for its top research results and huge business potential.

Abel has established strong joint venture/strategic partnerships with leading biotech companies and academic institutions, including Avalon GloboCare (NASDAQ:AVCO), Guangzhou Darui, Xikang Biotechnology and Cornell University.